ATHX earnings call for the period ending June 30, 2019.
News & Analysis: Athersys
The FDA has given the company's lead drug platform a potential leg up in development.
ATHX earnings call for the period ending March 31, 2019.
The stem cell pioneer announced an update with its most important collaborator.
ATHX earnings call for the period ending December 31, 2019.
An investment bank analyst predicts off-the-hook gains from Athersys' "off-the-shelf" stem cell treatments.
But beware: Not all that glitters is gold.
Athersys, Inc. will present phase 2 data for its stem cell therapy as a treatment for ischemic stroke on April 19th.
See which companies suffered the worst clinical setbacks in the week ending May 2.
Athersys shares motored higher after being granted a handful of new patents in Japan.